Casimersen - Generic Drug Details

What are the generic sources for casimersen and what is the scope of patent protection?

Casimersen is the generic ingredient in one branded drug marketed by Sarepta Theraps Inc and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Casimersen has ninety patent family members in twenty-five countries.

One supplier is listed for this compound.

Summary for casimersen

International Patents:	90
US Patents:	6
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	3
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for casimersen
What excipients (inactive ingredients) are in casimersen?	casimersen excipients list
DailyMed Link:	casimersen at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for casimersen

Constraining patent/regulatory exclusivity:

9,228,187

Dosage:

SOLUTION;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for casimersen

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Kevin Flanigan	Phase 2
Sarepta Therapeutics, Inc.	Phase 2
Sarepta Therapeutics, Inc.	Phase 3

See all casimersen clinical trials

Pharmacology for casimersen

Drug Class	Antisense Oligonucleotide
Physiological Effect	Increased Protein Synthesis

Anatomical Therapeutic Chemical (ATC) Classes for casimersen

M09AX	Other drugs for disorders of the musculo-skeletal system
M09A	OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM
M09	OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM
M	Musculo-skeletal system

US Patents and Regulatory Information for casimersen

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026-001	Feb 25, 2021		RX	Yes	Yes	9,228,187		Y	Y
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026-001	Feb 25, 2021		RX	Yes	Yes	9,758,783
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026-001	Feb 25, 2021		RX	Yes	Yes
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026-001	Feb 25, 2021		RX	Yes	Yes	9,447,415		Y	Y
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026-001	Feb 25, 2021		RX	Yes	Yes	10,781,450
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026-001	Feb 25, 2021		RX	Yes	Yes	10,287,586		Y	Y

Expired US Patents for casimersen

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026-001	Feb 25, 2021	10,533,174
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026-001	Feb 25, 2021	9,447,415
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026-001	Feb 25, 2021	9,416,361

International Patents for casimersen

Country	Patent Number	Title	Estimated Expiration
South Korea	20220031125	안티센스 분자 및 이를 이용한 질환 치료방법 (Antisense Molecules and Methods for Treating Pathologies)
Slovenia	2499249
Poland	2499249
Lithuania	2499249
Israel	297299	אוליגונוקלאוטידי אנטיסנס לגרימת דילוג אקסון בגן דיסטרופין (Antisense oligonucleotides for inducing exon skipping in the dystrophin gene)
South Korea	20180004745

Market Dynamics and Financial Trajectory for Casimersen

Last updated: July 29, 2025

Introduction

Casimersen (brand name Amondys 45) is an antisense oligonucleotide drug developed by Sarepta Therapeutics for the treatment of Duchenne Muscular Dystrophy (DMD) caused by mutations amenable to exon 45 skipping. As one of several exon-skipping therapies, casimersen's development and commercialization are influenced by intricate market factors, competitive landscapes, regulatory mechanisms, and financial considerations. This article assesses the current market dynamics and projects the financial trajectory of casimersen, offering insights crucial for stakeholders in the pharmaceutical sector.

Market Landscape of Duchenne Muscular Dystrophy

DMD is a rare, life-threatening genetic disorder primarily affecting young boys, with an estimated prevalence of 1 in 3,500 to 5,000 male births globally. The condition results from mutations in the dystrophin gene, leading to progressive muscle degeneration. Current treatment options focus on symptom management, but recent advances—particularly exon-skipping therapies—aim to modify disease progression.

The global DMD therapeutics market was valued at approximately USD 206 million in 2020 and projected to grow at a compound annual growth rate (CAGR) of 12-15% over the next decade [1]. This robust growth is driven by increased diagnosis rates, ongoing clinical development of novel therapies, and expanding approval of targeted drugs such as casimersen and its competitors.

Regulatory and Clinical Milestones of Casimersen

Casimersen received accelerated approval from the U.S. Food and Drug Administration (FDA) in February 2021 based on a surrogate endpoint—exon 45 skipping activity—highlighting the regulatory recognition of its therapeutic potential. The approval marks a significant milestone, positioning casimersen among a limited portfolio of exon-skipping drugs including eteplirsen and golodirsen.

Clinical development has demonstrated reductions in dystrophin deficiency, although long-term efficacy and safety data remain under evaluation. The FDA’s conditional approval emphasizes the urgent need for effective therapies but also indicates potential hurdles related to post-marketing studies and evidentiary standards.

Market Dynamics Influencing Casimersen

1. Competitive Landscape

The DMD market features a limited number of approved therapies, predominantly from Sarepta Therapeutics and BioMarin Pharmaceutical. Eteplirsen (Exondys 51), approved in 2016, was the first exon 51 skipping agent, while golodirsen (Vyondys 53) and viltolarsen (Viltepso) serve similar mutations with varying efficacy profiles.

Casimersen's capacity to differentiate itself hinges on mutation-specific efficacy, safety profiles, pricing, and reimbursement pathways. Its approval as an exon 45 skipping agent makes it a critical choice for patients harboring this mutation, thus creating a niche but significant market segment.

2. Reimbursement and Market Access

Reimbursement policies significantly impact casimersen's sales trajectory. Payor acceptance depends on demonstrated clinical benefit over comparators and cost-effectiveness. The high price of exon-skipping therapies ($300,000 – $500,000 annually) poses challenges, especially in markets with constrained healthcare budgets.

In the U.S., MSAs (Medicare and Medicaid) and private insurers influence patient access. Early negotiations and health technology assessments (HTAs) in Europe, such as NICE evaluations, shape international access. Successful reimbursement pathways will determine the therapy's adoption rate and revenue generation.

3. Clinical Adoption and Prescriber Acceptance

Physician awareness, comfort with the drug's efficacy, and the perceived risk-benefit profile influence prescribing patterns. Continued clinical data support and real-world evidence networks are vital for expanding casimersen’s utilization.

Moreover, combination with other therapies or inclusion in clinical trial extensions could expand its application and acceptance within standard care protocols.

Financial Trajectory of Casimersen

1. Revenue Projections

Initial sales of casimersen are expected to be modest, reflecting its recent launch and mutation-specific application. For 2023, analyst estimates project revenues in the range of USD 50 – 100 million, contingent on reimbursement outcomes and market penetration [2].

As the drug gains broader acceptance and clinical evidence accrues, revenues are projected to grow at a CAGR of 10-15% over the next five years, potentially reaching USD 300-400 million by 2028. This projection assumes favorable reimbursement, increased diagnosis of exon 45 mutations, and consistent prescriber uptake.

2. Cost Structure and Profitability

Development and commercialization costs for casimersen encompass R&D expenses, manufacturing, regulatory compliance, and commercialization. Given Sarepta's established infrastructure, marginal costs per patient are expected to decline with scale, potentially leading to healthier profit margins over time.

Gross margins could approach 60-70% once revenues stabilize post-launch. However, high marketing expenses and reimbursement negotiations may temporarily suppress profitability.

3. Investment and Funding Implications

The promising market potential of casimersen fuels continued investment from Sarepta and strategic partners. Capital allocation towards expanding indication labels, improving delivery mechanisms, and post-marketing studies is critical. Additionally, the drug's success influences Sarepta’s valuation and strategic positioning in the rare disease space.

Future Outlook and Market Challenges

The outlook for casimersen remains cautiously optimistic. While initial approval marks a critical breakthrough, extensive phase IV data and real-world outcomes will determine its long-term market dominance. Competitive pressures from emerging therapies, such as gene editing (e.g., CRISPR-based approaches), may challenge the traditional exon-skipping paradigm.

Market challenges include reimbursement hurdles, limited mutation-specific indications, and ongoing questions regarding long-term efficacy and safety.

Strategic Recommendations

• Data Generation: Accelerate post-marketing studies to substantiate efficacy, which will facilitate broad reimbursement negotiations.

• Market Expansion: Explore potential for label expansion to other exon mutations or combination therapies.

• Pricing & Access Strategies: Develop tiered pricing models and patient assistance programs to improve market access.

• Stakeholder Engagement: Strengthen collaborations with payers, patient groups, and clinicians to bolster adoption.

Key Takeaways

• Casimersen is a mutation-specific exon 45 skipping therapy with promising clinical and regulatory milestones shaping its market potential.

• Market access remains a primary driver; reimbursement success will determine revenue trajectory.

• Revenue forecasts suggest a gradual increase, with potential to reach USD 300-400 million by 2028, contingent upon clinical validation and competitive landscape evolution.

• Ongoing clinical data collection and strategic positioning will be pivotal in establishing long-term market share.

• Sarepta's continued innovation and stakeholder engagement are vital for maximizing casimersen’s commercial and therapeutic impact.

FAQs

1. What distinguishes casimersen from other exon-skipping therapies?
Casimersen specifically targets exon 45 mutations, serving a niche patient population distinct from therapies targeting exons 51 or 53. This mutation specificity allows tailored treatment options within the DMD landscape.

2. How does regulatory approval impact casimersen’s market potential?
FDA accelerated approval facilitates early market entry but accentuates the need for ongoing confirmatory studies to sustain approval and expand clinical and reimbursement acceptance.

3. What pricing strategies could influence casimersen’s adoption?
Premium pricing aligns with the rare disease model but may challenge reimbursement. Tiered pricing, value-based agreements, and patient assistance programs can promote access.

4. How does the competitive landscape affect casimersen’s revenues?
Limited approved exon-skipping drugs minimize immediate competition; however, emerging gene therapies may threaten long-term market share, necessitating continuous innovation.

5. What are the key risks to casimersen’s financial success?
Regulatory uncertainties, reimbursement hurdles, clinical efficacy concerns, and competitive innovations pose significant risks to its financial trajectory.

References

[1] Market Research Future. "DMD Therapeutics Market Analysis." 2021.
[2] Sarepta Therapeutics Financial Reports. "Q4 and FY2022 Financial Results." 2023.